{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:59:25Z","timestamp":1785315565778,"version":"3.55.0"},"reference-count":24,"publisher":"Baskent University","issue":"Supp 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.6002\/ect.mesot2025.p133","type":"journal-issue","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:21:41Z","timestamp":1785237701000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Brod M, McLeod L, Markova D, et al. Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES). J Patient Rep Outcomes. 2021;5(1):70. doi:10.1186\/s41687-021-00320-2","DOI":"10.1186\/s41687-021-00320-2"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Brod M, Waldman LT, Smith A, Karpf D. Assessing the patient experience of hypoparathyroidism symptoms: development of the hypoparathyroidism patient experience scale-symptom (HPES-Symptom). Patient. 2020;13(2):151-162. doi:10.1007\/s40271-019-00388-5","DOI":"10.1007\/s40271-019-00388-5"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Wilde D, Wilken L, Stamm B, et al. The HPQ-development and first administration of a questionnaire for hypoparathyroid patients. JBMR Plus. 2020;4(1):e10245. doi:10.1002\/jbm4.10245","DOI":"10.1002\/jbm4.10245"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Cusano NE, Rubin MR, Bilezikian JP. PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. Expert Rev Endocrinol Metab. 2015;10(1):5-13. doi:10.1586\/17446651.2015.971755","DOI":"10.1586\/17446651.2015.971755"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Yao L, Li J, Li M, et al. Parathyroid hormone therapy for managing chronic hypoparathyroidism: a systematic review and meta-analysis. J Bone Miner Res. 2022;37(12):2654-2662. doi:10.1002\/jbmr.4676","DOI":"10.1002\/jbmr.4676"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Yucesan E, Goncu B, Basoglu H, et al. Fresh tissue parathyroid allotransplantation with short-term immunosuppression: 1-year follow-up. Clin Transplant. 2017;31(11)doi:10.1111\/ctr.13086","DOI":"10.1111\/ctr.13086"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Rejnmark L. Treatment of hypoparathyroidism by re-establishing the effects of parathyroid hormone. Endocrinol Metab (Seoul). 2024;39(2):262-266. doi:10.3803\/EnM.2024.1916","DOI":"10.3803\/EnM.2024.1916"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Buttner M, Singer S, Taylor K. Quality of life in patients with hypoparathyroidism receiving standard treatment: an updated systematic review. Endocrine. 2024;85(1):80-90. doi:10.1007\/s12020-024-03807-2","DOI":"10.1007\/s12020-024-03807-2"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. G\u00f6nc\u00fc B, Salepcio\u011flu H, Karatoprak U, et al. Evaluation of parathyroid transplantation waiting duration of hypoparathyroidism patients. Sa\u011fl\u0131k Hizmetleri ve E\u011fitimi Dergisi. 2021;5(2):48-52. doi:10.29228\/JOHSE.11","DOI":"10.29228\/JOHSE.11"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Zhang JLH, Appelman-Dijkstra NM, Schepers A. Parathyroid allotransplantation: a systematic review. Med Sci (Basel). 2022;10(1)doi:10.3390\/medsci10010019","DOI":"10.3390\/medsci10010019"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Devon K, Tinckam K, Humar A, et al. Successful deceased donor parathyroid allotransplantation: a novel approach in a patient with severe refractory hypoparathyroidism after thyroidectomy for thyroid cancer. Thyroid. 2024;34(8):1058-1061. doi:10.1089\/thy.2024.0115","DOI":"10.1089\/thy.2024.0115"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Goncu B, Yucesan E, Salepcioglu Kaya H, Kazancioglu R, Ersoy YE, Akcakaya A. The challenge of preoperative panel reactive antibody positivity in parathyroid transplantation. Exp Clin Transplant. 2024;22(Suppl 1):233-242. doi:10.6002\/ect.MESOT2023.P59","DOI":"10.6002\/ect.MESOT2023.P59"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Goncu B, Salepcioglu Kaya H, Yucesan E, Ersoy YE, Akcakaya A. Graft survival effect of HLA-A allele matching parathyroid allotransplantation. J Investig Med. 2021;69(3):785-788. doi:10.1136\/jim-2020-001648","DOI":"10.1136\/jim-2020-001648"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Diez JJ, Anda E, Sastre J, et al. Permanent postoperative hypoparathyroidism: an analysis of prevalence and predictive factors for adequacy of control in a cohort of 260 patients. Gland Surg. 2020;9(5):1380-1388. doi:10.21037\/gs-20-288","DOI":"10.21037\/gs-20-288"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Yucesan E, Goncu B, Ozdemir B, Idiz O, Ersoy YE, Aysan E. Importance of HLA typing, PRA and DSA tests for successful parathyroid allotransplantation. Immunobiology. 2019;224(4):485-489. doi:10.1016\/j.imbio.2019.05.007","DOI":"10.1016\/j.imbio.2019.05.007"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Nelson L, Ing SW, Rubin MR, et al. Psychometric analysis of the patient-reported hypoparathyroidism symptom diary symptom subscale using data from two clinical trials. Patient Relat Outcome Meas. 2023;14:355-367. doi:10.2147\/PROM.S414794","DOI":"10.2147\/PROM.S414794"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Iqbal K, Dass N, Gip C, Vila J, Rylands AJ, Marelli C. Defining the characteristics of chronic hypoparathyroidism not adequately controlled on conventional therapy: consensus findings of three European Delphi panels. Adv Ther. 2019;36(11):3007-3016. doi:10.1007\/s12325-019-01102-5","DOI":"10.1007\/s12325-019-01102-5"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Tsourdi E, Amrein K, Meier C, et al. Consensus-based recommendations for the diagnosis, treatment, and monitoring of hypoparathyroidism: insights from the DACH region. Calcif Tissue Int. 2025;116(1):107. doi:10.1007\/s00223-025-01414-5","DOI":"10.1007\/s00223-025-01414-5"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Ersoy YE, Goncu B, Yucesan E, Salepcioglu Kaya H, Kazancioglu R, Akcakaya A. An alternative and up-to-date recommendation for a proper site for parathyroid transplantation: the omentum. Exp Clin Transplant. 2024;22(Suppl 1):102-109. doi:10.6002\/ect.MESOT2023.O17","DOI":"10.6002\/ect.MESOT2023.O17"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Diez JJ, Anda E, Perez-Corral B, et al. Prevalence of chronic postsurgical hypoparathyroidism not adequately controlled: an analysis of a nationwide cohort of 337 patients. Front Endocrinol (Lausanne). 2024;15:1464515. doi:10.3389\/fendo.2024.1464515","DOI":"10.3389\/fendo.2024.1464515"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Graham T, Shoback DM, Abbott L, et al. Early U.S. real-world treatment patterns and outcomes in palopegteriparatide treatment for patients with hypoparathyroidism. Endocr Pract. 2025;31(12):1568-1575. doi:10.1016\/j.eprac.2025.08.008","DOI":"10.1016\/j.eprac.2025.08.008"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Hepsen S, Akhanli P, Sakiz D, et al. The effects of patient and disease-related factors on the quality of life in patients with hypoparathyroidism. Arch Osteoporos. 2020;15(1):75. doi:10.1007\/s11657-020-00759-8","DOI":"10.1007\/s11657-020-00759-8"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Rejnmark L. Quality of life in hypoparathyroidism. Endocrine. 2018;59(2):237-238. doi:10.1007\/s12020-017-1479-y","DOI":"10.1007\/s12020-017-1479-y"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Khan AA, Rubin MR, Schwarz P, et al. Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway Trial. J Bone Miner Res. 2023;38(1):14-25. doi:10.1002\/jbmr.4726","DOI":"10.1002\/jbmr.4726"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:03:16Z","timestamp":1785312196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/supplement\/2026\/24\/6\/2\/345\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"Supp 2","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.mesot2025.p133","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}